Share This Article:

An Innovative Concept of High-Dose-Rate (HDR) Intracavitary Brachytherapy with an Intrauterine Inflatable Balloon for Endometrial Carcinoma

Abstract Full-Text HTML Download Download as PDF (Size:2909KB) PP. 878-883
DOI: 10.4236/jct.2014.59095    2,593 Downloads   3,188 Views  

ABSTRACT

Purpose: Curative radiation therapy is an established treatment option for non-surgical patients with early-stage endometrial carcinoma. Dosimetric analyses were performed using a single tandem, double tandem, Heyman capsules, and an inflatable intrauterine balloon to assess the dose homogeneity and conformality in the definitive treatment of inoperable endometrial cancer. Methods and Materials: Patients’ informed-consent was obtained. Dosimetric analyses were performed using four different after-loading applicators to assess the dose homogeneity and conformality of isodose to the three-dimensional (3-D) shape of the target volume (uterus) based on CT data in four patients (n = 4). The single tandem and double tandems were standard Fletcher-type (Nucletron Corporation, Columbia, MD). Heyman capsules were the disposable after-loading type (Radiation Products Design, Inc., Albertville, MN). The inflatable balloon with a central bi-lumen catheter was the Mammo Site Radiation Therapy System (Proxima Therapeutics, Alpharetta, GA) that is currently used for local breast brachytherapy. Treatment planning and dosimetric analyses for all four techniques were done with HDR PLATO Brachytherapy (v14.2.3) Software (Nucletron Corporation). Results: The average dose gradient within the target (uterine wall) is highest with the tandem methods, followed by Heyman capsules. The intrauterine balloon method showed the least dose gradient across the uterine wall. The corresponding average homogeneity indices were 3.81, 3.83, 2.97, 2.50 for single tandem, double tandem, Heyman capsules, and intrauterine balloon respectively. Conclusions: The intra-uterine inflatable balloon appears to have the best overall dosimetric advantages for the treatment of the uterine wall. Furthermore, the potential ease of use, shorter time of applicator placement, and better patient comfort warrant further investigation and subsequent clinical implementation.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Patel, A. , Cummins, S. , Luh, J. and Eng, T. (2014) An Innovative Concept of High-Dose-Rate (HDR) Intracavitary Brachytherapy with an Intrauterine Inflatable Balloon for Endometrial Carcinoma. Journal of Cancer Therapy, 5, 878-883. doi: 10.4236/jct.2014.59095.

References

[1] American Cancer Society (2013) Endometrial (Uterine) Cancer.
http://www.cancer.org/Cancer/EndometrialCancer/DetailedGuide/endometrial-uterine-cancer-key-statistics
[2] Nguyen, T.V. and Petereit, D.G. (1998) High-Dose-Rate Brachytherapy for Medically Inoperable Stage I Endometrial Cancer. Gynecologic Oncology, 71, 196-203. http://dx.doi.org/10.1006/gyno.1998.5148
[3] Fishman, D.A., Roberts, K.B., Chambers, J.T., et al. (1996) Radiation Therapy as Exclusive Treatment for Medically Inoperable Patients with Stage I and II Endometrioid Carcinoma with Endometrium. Gynecologic Oncology, 61, 189-196. http://dx.doi.org/10.1006/gyno.1996.0123
[4] Rouanet, P., Dubois, J.B., Gely, S., et al. (1993) Exclusive Radiation Therapy in Endometrial Carcinoma. International Journal of Radiation Oncology*Biology*Physics, 26, 223-228.
[5] Lehoczky, O., Bosze, P., Ungar, L., et al. (1991) Stage I Endometrial Carcinoma: Treatment of Nonoperable Patients with Intracavitary Radiation Therapy Alone. Gynecologic Oncology, 43, 211-216. http://dx.doi.org/10.1016/0090-8258(91)90022-W
[6] Kucera, H., Knocke, T.H., Kucera, E., et al. (1998) Treatment of Endometrial Carcinoma with High-Dose-Rate Brachytherapy Alone in Medially Inoperable Stage I Patients. Acta Obstetricia et Gynecologica Scandinavica, 77, 1008-1012. http://dx.doi.org/10.1080/j.1600-0412.1998.771011.x
[7] Knocke, T.H., Kucera, H., Weidinger, B., et al. (1997) Primary Treatment of Endometrial Carcinoma with Highdose-Rate Brachytherapy: Results of 12 Years of Experience with 289 Patients. International Journal of Radiation Oncology*Biology*Physics, 37, 359-365.
[8] Kupelian, P.A., Eifel, P. and Tornos, C. (1993) Treatment of Endometrial Carcinoma with Radiation Therapy Alone. International Journal of Radiation Oncology*Biology*Physics, 27, 817-824.
[9] Grisby, P.W., Kuske, R.R., Perez, C.A., et al. (1987) Medically Inoperable Stage I Adenocarcinoma of the Endometrium Treated with Radiotherapy Alone. International Journal of Radiation Oncology*Biology*Physics, 13, 483-488.
[10] Niazi, T.M., Souhami, L., Portelance, L., et al. (2005) Long-Term Results of High-Dose-Rate Brachytherapy in the Primary Treatment of Medically Inoperable Stage I-II Endometrial Carcinoma. International Journal of Radiation Oncology*Biology*Physics, 63, 1108-1113.
[11] Coon, D., Beriwal, S., Heron, D.E., et al. (2008) High-Dose-Rate Rotte “Y” Applicator Brachytherapy for Definitive Treatment of Medically Inoperable Endometrial Cancer: 10-Year Results. International Journal of Radiation Oncology*Biology*Physics, 71, 799-783.
[12] Potter, R., Gerbaulet, A. and Haie-Meder, C. (2002) The GEC-ESTRO Handbook of Brachytherapy. Endometrial Cancer. http://estro-education.org/publications/Documents/IB%2015%2029072002%20 Endometrial%20Cancer%20print_procTW.pdf
[13] Nag, S., Erickson, B., Parikh, S., et al. (2000) The American Brachytherapy Society Recommendations for High-Dose-Rate Brachytherapy for Carcinoma of the Endometrium. International Journal of Radiation Oncology*Biology*Physics, 48, 779-790.
[14] Vicini, F., Beitsch, P., Quiet, C., et al. (2011) Five-Year Analysis of Treatment Efficacy and Cosmesis by the American Society of Breast Surgeons Mammo Site Breast Brachytherapy Registry Trial in Patients Treated with Accelerated Partial Breast Irradiation. International Journal of Radiation Oncology*Biology*Physics, 79, 808-817.
[15] Miller, D.A., Richardson, S. and Grigsby, P.W. (2010) A New Method of Anatomically Conformal Vaginal Cuff HDR Brachytherapy. Gynecologic Oncology, 116, 413-418.
http://dx.doi.org/10.1016/j.ygyno.2009.10.044

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.